Champions Oncology, Inc. (CSBR) financial statements (2022 and earlier)

Company profile

Business Address 855 N. WOLFE STREET
BALTIMORE, MD 21205
State of Incorp. DE
Fiscal Year End April 30
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

1/31/2022
TTM
4/30/2021
4/30/2020
4/30/2019
4/30/2018
4/30/2017
4/30/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments8,7014,6878,3423,2378563,2952,585
Cash and cash equivalents8,7014,6878,3423,2378563,2952,585
Receivables8,5636,9864,7704,3773,9172,2741,312
Other undisclosed current assets561957385308287300443
Total current assets:17,82512,63013,4977,9225,0605,8694,340
Noncurrent Assets
Operating lease, right-of-use asset8,4188,5212,798
Property, plant and equipment6,9916,0903,9932,5462,0831,216618
Intangible assets, net (including goodwill)335335335669669669669
Goodwill335335335669669669669
Restricted cash and investments    150150150
Other noncurrent assets1515128128116107 
Total noncurrent assets:15,75914,9617,2543,3433,0182,1421,437
TOTAL ASSETS:33,58427,59120,75111,2658,0788,0115,777
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5,7694,1255,6423,9872,7492,5372,167
Accounts payable3,7431,8943,1402,8072,1541,8521,896
Accrued liabilities2,0262,2312,5021,180595685271
Deferred revenue8,7016,2565,815
Debt  62816   
Deferred revenue and credits4,7044,9103,139
Other liabilities15      
Other undisclosed current liabilities1,014818 4,022   
Total current liabilities:15,49911,19912,0858,0257,4537,4475,306
Noncurrent Liabilities
Long-term debt and lease obligation8,6188,7833,170 163859
Capital lease obligations 163859
Operating lease, liability8,6188,7833,170
Liabilities, other than long-term debt, including:231181178151151121165
Deferred rent credit   851
Other liabilities231181178151622164233
Other undisclosed liabilities, other than long-term debt   (851)(471)(43)(68)
Other undisclosed noncurrent liabilities   85145559
Total noncurrent liabilities:8,8498,9643,3481,002622164233
Total liabilities:24,34820,16315,4339,0278,0757,6115,539
Stockholders' equity
Stockholders' equity attributable to parent9,2367,4285,3182,2383400238
Common stock1413131211119
Treasury stock, value    (1,252)(1,252)(1,252)
Additional paid in capital80,86079,94577,97872,92472,07070,99163,947
Accumulated deficit(71,638)(72,530)(72,673)(70,698)(70,826)(69,350)(62,466)
Total stockholders' equity:9,2367,4285,3182,2383400238
TOTAL LIABILITIES AND EQUITY:33,58427,59120,75111,2658,0788,0115,777

Income statement (P&L) ($ in thousands)

1/31/2022
TTM
4/30/2021
4/30/2020
4/30/2019
4/30/2018
4/30/2017
4/30/2016
Revenues46,79641,04032,12327,06720,24115,41111,182
Revenue, net20,24115,41111,182
Cost of revenue
(Cost of Goods and Services Sold)
(23,035)(21,446)     
Gross profit:23,76119,59432,12327,06720,24115,41111,182
Operating expenses(46,307)(40,674)(33,926)(26,797)(21,595)(22,220)(21,498)
Other undisclosed operating income23,03521,446     
Operating income (loss):489366(1,803)270(1,354)(6,809)(10,316)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
1871(42)(39)(89)(56)(38)
Income (loss) from continuing operations before income taxes:507437(1,845)231(1,443)(6,865)(10,354)
Income tax expense(69)(75)(130)(103)(33)(19)(92)
Net income (loss):438362(1,975)128(1,476)(6,884)(10,446)
Other undisclosed net income attributable to parent     00
Net income (loss) available to common stockholders, diluted:438362(1,975)128(1,476)(6,884)(10,446)

Comprehensive Income ($ in thousands)

1/31/2022
TTM
4/30/2021
4/30/2020
4/30/2019
4/30/2018
4/30/2017
4/30/2016
Net income (loss):438362(1,975)128(1,476)(6,884)(10,446)
Comprehensive income (loss), net of tax, attributable to parent:438362(1,975)128(1,476)(6,884)(10,446)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: